Paolo Ius
University of Padua
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paolo Ius.
European Journal of Cardio-Thoracic Surgery | 2010
Carlo Valfrè; Paolo Ius; Giuseppe Minniti; Loris Salvador; Tomaso Bottio; Francesco Cesari; Giulio Rizzoli; Gino Gerosa
OBJECTIVE The Hancock II (HII) is a second-generation porcine bioprosthesis introduced into clinical use in 1982. This study aimed to evaluate very long-term outcomes for the HII valve in a large patient population. METHODS Between May 1983 and November 1993, 517 consecutive patients (pts) (309 male, mean age: 64+/-9 years) underwent valve replacement (VR) surgery with HII, with 302 (58.4%) in the aortic VR (AVR) and 215 (41.6%) in the mitral VR (MVR) position, respectively. At implant, 106 pts (20.5%) were <60 years of age (G1), while 411 (79.5%) were > or =60 years of age (G2). The 25-year follow-up was complete for all pts at a median of 12 years (range: 0-25). RESULTS Long-term death occurred in 208 AVR and in 165 MVR pts. Survival at 15 and 20 years was 39.5% and 23.3% in AVR pts and 39.0% and 15.8% in MVR pts. At 25 years the survival of MVR pts was 13.7% (four pts at risk). Late freedom from re-operation was 85.5% and 79.3% at 15 and 20 years in the AVR pts and 73.3% and 52.8% in the MVR pts, respectively. In the AVR population, 20-year freedom from re-operation was 52.2% in G1 pts and 86.8% in G2 pts (p<0.0001), while in the MVR population it was 41.4% in G1 pts and 61.9% in G2 pts (p=0.201), respectively. CONCLUSIONS These results confirm the excellent long-term performance of the HII bioprosthesis.
The Journal of Thoracic and Cardiovascular Surgery | 2003
Tomaso Bottio; Gaetano Thiene; Elena Pettenazzo; Paolo Ius; Uberto Bortolotti; Giulio Rizzoli; Carlo Valfrè; Dino Casarotto; Marialuisa Valente
BACKGROUND AND OBJECTIVES The Hancock II bioprosthesis is a second-generation porcine valve xenograft treated with the detergent sodium dodecyl sulphate (T6) to retard calcification. The aim of this investigation was to study the gross and microscopic features in Hancock II explants to assess the structural changes occurring with time. METHODS Among 1382 Hancock II bioprostheses (701 isolated aortic, 421 isolated mitral, 130 double) implanted from 1983 to 1997 in 1252 patients, 22 (16 mitral, 6 aortic) were removed at reoperation until 1999 and were available for pathological investigation: infective endocarditis occurred in 5 and structural deterioration in 8, whereas in the remaining 9 xenografts reoperation was performed for nonstructural valve deterioration (paravalvular leak in 4 and prophylactic replacement in 5). Morphological investigation consisted of gross examination and x-ray, histologic, immunohistochemistry, electron microscopic, and atomic absorption spectroscopic examination. RESULTS The cause of structural valve deterioration was dystrophic calcification in 4 cases (1 aortic, 3 mitral; range of time graft was in place, 101 to 144 months), non-calcium-related tears in 3 cases (all mitral, range 121 to 163 months), and commissural dehiscence in 1 (aortic, range 156 months). Five of the nonstructural valve deterioration explants (range 42 to 122 months) showed only pinpoint mineralization at the commissures. Mean calcium content in nonstructural deterioration explants was 14.70 +/- 22.33 versus 99.11 +/- 81.52 mg/g in explants with structural valve deterioration. Electron microscopic examination showed early nuclei of mineralization mostly consisting of calcospherulae upon cell debris. Local or diffuse lipid insudation was observed in all but 2 explants and consisted of cholesterol clefts, lipid droplets, and lipid-laden macrophages featuring foam cells. The lipid insudation was the most plausible cause of tearing in 2 explants. CONCLUSIONS These pathologic findings support the clinical results of a delayed occurrence of structural failure of Hancock II bioprostheses and a mitigation of mineralization by the anti-calcification treatment. However, other factors such as lipid insudation may come into play in the long term.
American Journal of Cardiology | 1995
Fabio Chirillo; Paolo Ius; Oscar Totis; Andrea Bruni; Carlo Valfrè; Stritoni P
Abstract In conclusion, according to previous studies, 3,5–7 transthoracic echocardiography remains the most important technique for achieving an accurate and rapid diagnosis of mechanical complications of AMI. The addition of TEE and transgastric echocardiography is of great value in assessing the severity and the mechanism of mitral regurgitation to delineate complex lesions (very frequent in the present series) and to identify incomplete free wall rupture.
The Annals of Thoracic Surgery | 1992
Uberto Bortolotti; Paolo Ius; Gaetano Thiene; Marco Minarini; Aldo Milano; Carlo Valfrè; Enrico Talenti; Marialuisa Valente; Alessandro Mazzucco
Durability of a new bioprosthesis, the Meadox-Gabbay unileaflet pericardial xenograft, was evaluated by reviewing a series of 12 patients who received this device in the mitral position from 1983 to 1985. Bioprosthetic failure necessitated reoperation in 5 patients 21, 22, 53, 66, and 81 months after placement. Three patients died of cardiac failure after 31, 52, and 70 months; no postmortem examinations were done. In 2 of the 3 patients, an echocardiographic study had shown signs of valvular dysfunction. Pathological examination of five available explants revealed the presence of redundancy and stretching of the single pericardial leaflet in all of them; in one, this lesion alone caused severe prosthetic incompetence. Other pathological findings included cusp and commissural calcification and commissural tears with or without calcification. Histologic examination and electron microscopy showed intrinsic calcification involving both collagen bundles and cellular debris and various degrees of collagen disruption. In this limited series of patients, the Meadox-Gabbay pericardial xenograft demonstrated various modes of failure that markedly impair its durability and render it unsuitable as a cardiac valve substitute.
The Journal of Thoracic and Cardiovascular Surgery | 2006
Giulio Rizzoli; Salvatore Mirone; Paolo Ius; Elvio Polesel; Tomaso Bottio; Loris Salvador; Claudio Zussa; Gino Gerosa; Carlo Valfrè
Journal of Heart Valve Disease | 1998
Marialuisa Valente; Paolo Ius; Uberto Bortolotti; Enrico Talenti; Tomaso Bottio; Gaetano Thiene
Journal of Heart Valve Disease | 1996
Paolo Ius; Gaetano Thiene; Marco Minarini; Marialuisa Valente; Uberto Bortolotti; Enrico Talenti; Casarotto D
The Journal of Thoracic and Cardiovascular Surgery | 2006
Carlo Valfrè; Giulio Rizzoli; Claudio Zussa; Paolo Ius; Elvio Polesel; Salvatore Mirone; Tomaso Bottio; Gino Gerosa
The Journal of Thoracic and Cardiovascular Surgery | 1994
Claudio Zussa; Paolo Ius; Francesco Cesari; Carlo Yalfre; Oscar Totis; Carlo Canova; Paolo Pugina
Journal of Heart Valve Disease | 1996
Paolo Ius; Totis O; Chirillo F; Cavarzerani A; Claudio Zussa; Piccoli C; Carlo Valfrè